Optic Neuritis

• T-cell mediated autoimmune demyelination: The primary mechanism involves breakdown of immune tolerance to myelin antigens, particularly myelin oligodendrocyte glycoprotein (MOG) and myelin basic protein (MBP). CD4+ and CD8+ T cells infiltrate the optic nerve, initiating a Th1 and Th17-mediated inflammatory cascade. Activated T cells produce interferon-gamma (IFN-γ) and tumor necrosis factor-alpha (TNF-α), recruiting macrophages that phagocytose myelin sheaths surrounding axons. This demyelination disrupts saltatory conduction along the optic nerve, causing conduction block and slowed axonal transmission that manifests clinically as vision loss and impaired color perception.

• B-cell activation and antibody-mediated complement deposition: Autoreactive B cells produce immunoglobulins against myelin antigens, with IgG and IgM antibodies depositing along the optic nerve. Complement cascade activation (particularly C3 and C5) amplifies the inflammatory response, generating membrane attack complexes that directly damage myelin and oligodendrocytes. Interleukin-6 (IL-6) and B-cell activating factor (BAFF) support pathogenic B-cell expansion. The distinction between MOG-IgG positive and aquaporin-4 (AQP4)-IgG positive ON (associated with neuromyelitis optica spectrum disorder, NMOSD) involves different pathophysiologic mechanisms—MOG antibodies target surface MOG on oligodendrocytes, while AQP4 antibodies target aquaporin-4 channels on astrocytic endfeet, explaining the recurrent and often bilateral nature of AQP4-associated ON.

• Axonal loss and conduction block mechanisms: Early optic neuritis involves reversible conduction block without significant axonal loss, explaining the potential for dramatic visual recovery in many patients. Axonal loss is limited in initial episodes but accumulates with recurrent demyelinating events. Conduction block occurs because demyelinated segments lose the high sodium channel density necessary for action potential generation. The inflammation causes blood-brain barrier breakdown through matrix metalloproteinase (MMP-2 and MMP-9) upregulation and VEGF-mediated vascular permeability, allowing peripheral immune cell infiltration and edema formation within the optic nerve. Focal swelling (optic neuritis) versus diffuse nerve involvement predicts recovery patterns—more circumscribed inflammation generally permits better functional restoration.

• Gadolinium enhancement and inflammation dynamics: The acute inflammatory phase lasts 3-6 weeks, during which BBB breakdown allows gadolinium contrast penetration visible on MRI. This enhancement reflects active inflammation and immune cell infiltration. The subsequent resolution phase involves T-regulatory cell (Treg) expansion, IL-10 and TGF-β production, and gradual BBB restoration. Oligodendrocyte precursor cell (OPC) migration and remyelination occur over weeks to months, supporting functional recovery. Approximately 70% of demyelinated segments undergo remyelination, though remyelinated internodes are typically shorter and thinner than normal, partially explaining persistent subtle deficits even after apparent clinical recovery.

• Multiple sclerosis (MS) and demyelinating disease: MS represents the most important etiology and association in optic neuritis pathogenesis. Approximately 30-50% of ON patients develop clinically definite MS within 15 years (higher with abnormal brain MRI at ON presentation). The ONTT demonstrated that brain MRI abnormalities at ON presentation (≥3 lesions) increased 15-year MS risk to 56% compared to 22% in patients with normal brain MRI. MS-associated ON typically presents as unilateral retrobulbar inflammation and usually precedes other MS manifestations. The immunopathologic mechanisms overlap significantly with MS lesion formation in other CNS locations.

• Neuromyelitis optica spectrum disorder (NMOSD) and aquaporin-4 antibody disease: NMOSD presents with recurrent, often bilateral ON episodes distinguished by severe, incomplete recovery and higher recurrence risk. AQP4-IgG seropositivity (found in ~80% of NMOSD cases) identifies an astrocyte-directed pathogenic mechanism distinct from MS. MOG-IgG antibody-associated disease represents another distinct entity with acute, severe ON and possible recurrent episodes; MOG-ON affects a younger demographic including children and often precedes other neurologic manifestations. These antibody-positive conditions require different diagnostic approaches and treatment strategies than typical MS-associated ON.

• Inflammatory and systemic autoimmune conditions: Systemic lupus erythematosus (SLE) associates with ON through circulating immune complex deposition and direct B-cell autoreactivity. Sarcoidosis causes ON through granulomatous inflammation, typically presenting with bilateral involvement and chronic uveitis. Inflammatory bowel disease (Crohn's disease and ulcerative colitis) carry increased ON risk through molecular mimicry and T-cell cross-reactivity. Sjögren's syndrome predisposes to ON through exocrine gland-directed autoimmunity that extends to CNS myelin. Vasculitic conditions including polyarteritis nodosa and granulomatosis with polyangiitis (GPA) can involve the optic nerve through vasculitis-mediated inflammation.

• Infectious triggers and molecular mimicry: Viral infections preceding ON include Epstein-Barr virus (EBV), cytomegalovirus (CMV), and coronavirus infections (including SARS-CoV-2), potentially through molecular mimicry mechanisms where viral epitopes cross-react with myelin antigens. Bacterial infections including Borrelia burgdorferi (Lyme disease), Treponema pallidum (neurosyphilis), and Mycobacterium tuberculosis cause optic neuropathy through direct infection or inflammatory response. These infectious etiologies require serologic and CSF testing to differentiate from primary demyelinating ON.

• Medications and toxin exposures: Ethambutol, used in tuberculosis treatment, causes toxic optic neuropathy through direct axonal toxicity rather than demyelination, presenting with subacute vision loss and color vision defects distinguishable from demyelinating ON. Interferon-beta therapy (used for MS) paradoxically can precipitate or worsen ON in susceptible individuals. Immunosuppressive medications in the setting of immune reconstitution inflammatory syndrome (IRIS) can unmask or exacerbate demyelinating disease. Tobacco and heavy alcohol use carry associations with nutritional optic neuropathy that may present similarly to ON.

• Genetic and environmental risk factors: HLA-DRB1*15:01 allele strongly associates with MS and ON susceptibility, explaining ethnic and geographic variations in ON incidence. Environmental factors including EBV seropositivity status, latitude of residence (lower incidence at equator suggesting vitamin D insufficiency), and smoking history contribute to disease risk. Vitamin D insufficiency (25-hydroxyvitamin D <30 ng/mL) independently predicts higher ON and MS risk, though causality remains debated. Female sex, elevated BMI, and previous viral infections represent additional documented risk factors.

• Subacute vision loss: Vision loss in ON develops over hours to days, reaching nadir typically within 1-2 weeks. The vision loss is usually unilateral in typical MS-associated ON but may be bilateral or sequential in NMOSD and MOG-ON. Patients describe dimming or darkening of vision, often comparing it to a veil or shadow obscuring the visual field. The mechanism reflects conduction block and inflammatory edema compressing axons in the optic nerve. Severity ranges from mild (20/25 vision) to severe (counting fingers or hand motion), with most patients experiencing vision worse than 20/60 at presentation. The paradox of relatively preserved vision in some patients despite significant optic nerve inflammation reflects the brain's compensation mechanisms and less affected foveal fibers.

• Pain with eye movements (retrobulbar pain): Pain accompanies 90-95% of ON cases and represents a cardinal clinical feature. The pain is typically orbital or retrobulbar, worsened by horizontal eye movements (particularly with optic nerve extension on adduction), and described as dull, aching, or sharp. Pain severity peaks within days and gradually resolves over 1-2 weeks, typically preceding or accompanying visual improvement. The mechanism involves inflammation of nerve sheaths (meninges surrounding the nerve) and traction on inflamed structures. Pain severity does not correlate with ultimate visual outcome. In approximately 5-10% of cases, ON presents without pain, which should raise suspicion for alternative diagnoses (compression, toxins, nutritional deficiency, or infectious etiologies).

• Color vision defects and relative afferent pupillary defect (RAPD): Red desaturation (impaired perception of red color intensity compared to normal eye) represents an extremely sensitive early sign, sometimes occurring before measurable visual acuity loss. The mechanism reflects preferential involvement of the magnocellular pathway conveying color information through the parvocellular layers. RAPD (Marcus Gunn pupil) results from differential input to the pupillary light reflex pathway, with the affected eye showing less pupillary constriction when light is swung to it compared to the normal eye. RAPD represents a sensitive objective sign of optic nerve dysfunction and correlates with ON severity. The relative afferent defect quantifies the severity of demyelination using the swinging flashlight test—a more pronounced RAPD (>0.3 log unit difference) indicates more extensive nerve involvement.

• Visual field defects: Central scotomas (absolute or relative defects in the central 10-15 degrees) represent the most common pattern, reflecting involvement of central macular fibers in the retrobulbar optic nerve. Altitudinal field defects, arcuate defects, and generalized depression occur less commonly. The visual field defect pattern correlates with the anatomic location of maximum inflammation within the optic nerve cross-section. Paracentral scotomas present as vision loss just eccentric to fixation and often cause disproportionate visual disturbance relative to their size due to proximity to the foveolar representation.

• Dyschromatopsia: Beyond red desaturation, more sophisticated color vision testing (Farnsworth-Munsell 100 hue test or Hardy-Rand-Rittler testing) reveals characteristic blue-yellow color vision loss, reflecting parvocellular pathway preferential involvement. This blue-yellow dyschromatopsia helps differentiate demyelinating ON from other optic neuropathies causing red-green defects.

• Physical examination findings: The optic fundus appears normal or relatively normal in retrobulbar ON (affecting the optic nerve posterior to the optic disc), earning the classic phrase "the patient sees nothing, the doctor sees nothing" or retrobulbar presentation. In contrast, papillitis (anterior ON with disc involvement) presents with optic disc edema, blurring of disc margins, hyperemia, and possible hemorrhages around the disc. Optic nerve pallor may appear within weeks as inflammation resolves and demyelinated axons appear on fundoscopy. Venous sheathing (white perivascular sheathing) may occur as inflammation involves the venous component of the optic nerve.

• Important clinical variants:
• Bilateral ON: Suggests NMOSD (especially AQP4-IgG positive), MOG-ON, or simultaneous bilateral demyelination—requires urgent serology and CSF analysis
• Papillitis (anterior ON): ON with visible optic disc edema; more common in children and NMOSD; may present with more preserved initial vision than retrobulbar ON
• Longitudinally extensive transverse myelitis (LETM) with ON: NMOSD hallmark association (on myelitis on myelitis)
• Recurrent ON: Suggests NMOSD, MOG-ON, or MS with recurrent attacks; more common in antibody-mediated diseases
• Severe vision loss with incomplete recovery: Concerning for NMOSD or MOG-ON rather than typical MS-associated ON
• Pediatric ON: Different prognostic significance; higher rates of MOG-ON and NMOSD compared to adult ON; lower immediate MS risk but requires closer follow-up

• Clinical diagnosis based on presentation: ON diagnosis rests primarily on recognizing the clinical triad of subacute unilateral vision loss, pain with eye movements, and objective optic nerve dysfunction (RAPD, color vision defect, visual field defect) in a young adult without prior demyelinating history. However, the diagnosis requires integration with appropriate investigations to exclude alternative etiologies. The combination of retrobulbar pain and visual loss in the appropriate demographic creates a highly specific clinical pattern. Documentation of RAPD severity using the swinging flashlight test provides objective evidence of optic nerve dysfunction; quantification using neutral density filters (determining the log unit difference between eyes) correlates with demyelination extent.

• Visual function testing and quantification:
• Best-corrected visual acuity (BCVA): Measured using ETDRS chart at 4 meters provides standardized assessment; baseline BCVA at presentation predicts recovery (better baseline generally indicates better prognosis)
• Visual evoked potentials (VEP): Latency prolongation (P100 latency >120 ms) reflects demyelination-induced slowed conduction; VEP may remain abnormal for months despite clinical recovery; sensitivity ~95% for clinical ON but less specific (abnormal in other optic neuropathies)
• Humphrey visual field testing: Documents field defect pattern and severity; central scotomas in 50%, arcuate defects in 30%, altitudinal defects in 10%, generalized depression in 10%
• Color vision testing: Ishihara plates (simple screening) show red desaturation; formal testing with Hardy-Rand-Rittler plates or Farnsworth-Munsell demonstrates blue-yellow color axis abnormality characteristic of demyelinating ON

• Magnetic resonance imaging (MRI) assessment:
• Orbital/optic nerve MRI: T2-weighted and FLAIR sequences reveal optic nerve hyperintensity; gadolinium-enhanced T1 imaging shows contrast enhancement indicating active inflammation and BBB breakdown (marked gadolinium enhancement suggests acute inflammatory demyelination)
• Brain MRI with gadolinium: Critical for MS risk stratification; white matter lesions in >90% of MS patients ultimately developing disease; the presence of ≥3 asymptomatic brain lesions at ON presentation increases 15-year MS risk to 56% (ONTT data); infratentorial or juxtacortical lesions carry higher MS specificity; normal brain MRI substantially reduces MS risk
• Spinal cord MRI: Evaluates for concurrent myelitis (raising NMOSD suspicion); presence of myelitis correlates with higher disability outcomes; longitudinally extensive transverse myelitis (LETM, lesions spanning ≥3 vertebral segments) highly suggestive of NMOSD
• MRI findings NOT typical of demyelinating ON: Optic nerve enhancement involving >50% nerve length, intracranial masses, orbital masses, or enhancement of bilateral optic nerves suggests alternative diagnoses

• Serologic testing for antibody-mediated disease:
• Aquaporin-4 (AQP4)-IgG antibody: Positive in 80% of NMOSD; associated with severe, recurrent ON and incomplete recovery; found in <1% of MS patients; detection indicates different prognosis and treatment (requires long-term immunosuppression rather than beta-interferons)
• Myelin oligodendrocyte glycoprotein (MOG)-IgG antibody: Positive in MOG-ON disease (distinct from both MS and NMOSD); associated with younger patient demographics and recurrent severe ON; negative in MS and usually negative in AQP4-IgG positive disease
• Serum testing timing: Should be obtained at presentation or within early days; CSF testing (IgG index, oligoclonal bands) adds diagnostic information but less specific than serum antibodies

• Cerebrospinal fluid (CSF) analysis:
• Pleocytosis: Lymph

Before treating — confirm the phenotype

• Exclude mimics first: in a patient over ~50 with painless vision loss and disc edema, check ESR/CRP for giant cell arteritis, which is a sight-threatening emergency treated with high-dose corticosteroids without waiting for biopsy (ACR/EULAR giant cell arteritis guidance). Send AQP4-IgG and MOG-IgG before or at the time of steroid initiation, since serology changes long-term therapy.

First-line acute therapy

• IV corticosteroids: methylprednisolone 1 g IV daily for 3 days, typically followed by an oral prednisone taper — the regimen established by the Optic Neuritis Treatment Trial (ONTT) and carried forward as standard neuro-ophthalmology practice rather than as a formal society guideline recommendation. Mechanism: glucocorticoids suppress T-cell activation, downregulate MMP-mediated blood–brain barrier breakdown, and hasten resolution of intraneural edema, so recovery is faster — but the 6- to 12-month visual outcome is essentially unchanged.
• Oral prednisone alone — avoid as initial monotherapy: the ONTT oral arm used prednisone 1 mg/kg/day for 14 days and showed a higher rate of recurrent optic neuritis. This is not a formal contraindication and the finding has been debated as dose- and formulation-dependent, but standard-dose oral prednisone is not the correct initial choice.

Escalation for steroid-refractory or severe attacks

• Plasma exchange (PLEX): removes pathogenic IgG and complement components; most useful in severe, poorly recovering, AQP4-IgG-positive attacks, and best when started early (American Society for Apheresis supports apheresis for steroid-refractory CNS demyelinating attacks).
• IVIG: alternative when PLEX is unavailable or in MOG-antibody disease.

Definitive/long-term (disease-modifying) therapy — driven by the underlying disease

• MS-associated ON: initiate a disease-modifying therapy (interferon-beta, glatiramer, or a higher-efficacy agent such as an anti-CD20 antibody like ocrelizumab) per the AAN disease-modifying therapy guideline, especially when brain MRI shows demyelinating lesions.
• AQP4-IgG NMOSD: chronic immunosuppression — anti-CD20 (rituximab), anti-CD19 (inebilizumab), anti-IL-6R (satralizumab), or complement C5 blockade (eculizumab). MS drugs can worsen NMOSD and should not be used: interferon-beta, natalizumab, fingolimod and other sphingosine-1-phosphate modulators, and alemtuzumab. Complement inhibitors carry a boxed warning for meningococcal disease; vaccinate before starting.
• MOGAD: many single attacks need no chronic therapy; recurrent disease is treated with steroid-sparing immunotherapy such as IVIG or rituximab.
• No role for surgery; optic nerve sheath fenestration treats papilledema, not optic neuritis.

Complications of the disease

• Optic atrophy with permanent visual deficit: cumulative axonal loss from repeated demyelination produces retinal nerve fiber layer thinning on OCT and temporal disc pallor on fundoscopy weeks after the attack. Signals irreversible damage even when Snellen acuity returns to 20/20.
• Persistent subtle visual dysfunction: remyelinated internodes are shorter and thinner, so conduction stays slow — patients report reduced contrast sensitivity, depth-perception errors (Pulfrich phenomenon, from asymmetric interocular conduction delay), and a residual RAPD or prolonged VEP P100 latency despite "normal" acuity.
• Uhthoff phenomenon: transient visual dimming with exercise, fever, or hot showers, because heat further slows conduction across partially demyelinated segments. It is a symptom of prior injury, not a new attack — do not re-treat with steroids.
• Conversion to clinically definite multiple sclerosis: the single most important long-term complication; risk is driven by baseline brain MRI lesion burden. New neurologic symptoms in a different CNS location signal it.
• Recurrent and bilateral attacks with severe, incomplete recovery: strongly suggests AQP4-IgG NMOSD or MOGAD. Emergency — an acute NMOSD attack threatens blindness and warrants urgent steroids and consideration of plasma exchange, plus screening for concurrent longitudinally extensive transverse myelitis and area postrema/respiratory involvement.
• Misdiagnosis as a complication: a compressive lesion, giant cell arteritis, or infectious optic neuropathy that fails to improve on the expected trajectory is an emergency re-evaluation trigger. Vision that continues to worsen beyond about two weeks is not typical demyelinating ON.

Complications of treatment

• High-dose corticosteroids: hyperglycemia (unmasked by pulse dosing), insomnia and steroid psychosis, gastritis, immunosuppression with opportunistic infection, and — with repeated courses — avascular necrosis of the femoral head, signaled by new groin pain with weight-bearing. Emergency: fever or hypotension suggesting infection or adrenal insufficiency after abrupt taper.
• Plasma exchange: citrate-induced hypocalcemia (perioral paresthesias, Chvostek sign), hypotension, coagulopathy, and central line complications.
• B-cell depletion (rituximab, inebilizumab): hypogammaglobulinemia with recurrent infection, hepatitis B reactivation (screen before starting), and rarely PML.
• Complement inhibitors (eculizumab): emergency — encapsulated organism sepsis, especially Neisseria meningitidis; any fever demands immediate evaluation and empiric antibiotics.

• The buzzword triad: young woman, subacute monocular vision loss, pain worse with eye movement, plus an afferent pupillary defect. On the swinging flashlight test the affected pupil paradoxically dilates — the Marcus Gunn pupil (RAPD).
• "The patient sees nothing and the doctor sees nothing": two-thirds of adult cases are retrobulbar, so the fundus is normal acutely. A normal disc does not exclude the diagnosis; disc pallor appears only weeks later.
• Single best next step: MRI brain and orbits with gadolinium. It confirms optic nerve enhancement and, more importantly, stratifies MS risk by counting periventricular/juxtacortical/infratentorial white matter lesions. Imaging drives management more than any lab.
• The association examiners love: optic neuritis as the sentinel event of multiple sclerosis, with MS risk scaling to brain lesion burden on the presenting MRI (ONTT). Internuclear ophthalmoplegia in the same patient nails MS.
• Steroid pearl: IV methylprednisolone (1 g daily × 3 days, ONTT regimen) speeds recovery but does not change final visual acuity, and oral prednisone alone is the wrong answer — the ONTT oral arm (prednisone 1 mg/kg/day × 14 days) had a higher rate of recurrent optic neuritis.
• Red flags that force a different diagnosis: bilateral simultaneous involvement, severe loss with poor recovery, or recurrence → send AQP4-IgG (NMOSD) and MOG-IgG. Treating NMOSD with interferon-beta, natalizumab, fingolimod or another sphingosine-1-phosphate modulator, or alemtuzumab can make it worse.
• Common distractors to avoid:
• Painless vision loss with an altitudinal field defect and a swollen disc in an older patient is NAION — and if accompanied by jaw claudication, scalp tenderness, and elevated ESR/CRP, it is giant cell arteritis, a steroid emergency.
• Ethambutol and methanol cause toxic optic neuropathy: bilateral, painless, with central scotomas and red-green dyschromatopsia — not demyelinating ON.
• Bilateral disc swelling without vision loss or RAPD is papilledema from raised intracranial pressure, not optic neuritis.
• Uhthoff phenomenon — transient blurring with heat or exercise — reflects old demyelination, not a new relapse.